Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.12.2017 | Case report

Alemtuzumab

Cervical dysplasia: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Nesbitt C, et al. Incidence of cervical dysplasia in females receiving alemtuzumab: An Australian single centre observational study. Multiple Sclerosis Journal 23 (Suppl. 1): 908 abstr. EP1724, No. 3, 24 Oct 2017. Available from: URL: http://doi.org/10.1177/1352458517731285 [abstract] - Australia Nesbitt C, et al. Incidence of cervical dysplasia in females receiving alemtuzumab: An Australian single centre observational study. Multiple Sclerosis Journal 23 (Suppl. 1): 908 abstr. EP1724, No. 3, 24 Oct 2017. Available from: URL: http://​doi.​org/​10.​1177/​1352458517731285​ [abstract] - Australia
Metadaten
Titel
Alemtuzumab
Cervical dysplasia: 2 case reports
Publikationsdatum
01.12.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-39304-5

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Propranolol